Ítem
Acceso Abierto
Efectividad del Ácido Ibandrónico y Ácido Zoledrónico en el tratamiento de osteoporosis postmenopáusica : estudio multicéntrico.
| dc.contributor.advisor | Martínez Del Valle, Anacaona | |
| dc.contributor.advisor | Sierra Hincapié, Gloria María | |
| dc.creator | López Páez, Derly Maritza | |
| dc.creator | Vergara Perdomo, Dalia Inés | |
| dc.creator.degree | Especialista en Epidemiología (en Convenio con el CES) | |
| dc.date.accessioned | 2017-09-29T15:00:48Z | |
| dc.date.available | 2017-09-29T15:00:48Z | |
| dc.date.created | 2017-09-28 | |
| dc.date.issued | 2017 | |
| dc.description | INTRODUCCIÓN La osteoporosis postmenopáusica afecta a una gran proporción de mujeres en el mundo, la mayoría en edades superiores a 50 años, la incidencia de la enfermedad seguirá aumentando dado el envejecimiento de la población que se acompaña de aumento en el riesgo total de fracturas. OBJETIVO Evaluar la efectividad del ácido zoledrónico comparado con el ácido ibandrónico, para el manejo de la osteoporosis postmenopáusica en poblaciones de Medellín y Bogotá pertenecientes a la IPS Helpharma, quienes recibieron tratamiento por un período de 2 a 4 años. METODOLOGÍA Estudio analítico, de cohorte, retrospectivo de 277 pacientes con diagnóstico de osteoporosis postmenopáusica. Las pacientes fueron tratadas por un período de 2 a 4 años en la IPS Helpharma en las ciudades de Bogotá y Medellín. Se incluyeron 56 pacientes tratadas con ácido ibandrónico y 221 tratadas con ácido zoledrónico. Se realizó muestreo aleatorio estratificado por afijación proporcional y la distribución por ciudades fue Bogotá (n: 99 pacientes) y Medellín (n: 178 pacientes). RESULTADOS El ácido ibandrónico obtuvo una mayor ganancia en T-score a nivel lumbar que femoral (6% vs1,5%), el FRAX mayor disminuyó en un 0,5% y el FRAX de cadera tuvo una ganancia de 0,1%. El ácido zoledrónico mostró ganancia en T-score lumbar del 11% y femoral del 5,4%, el FRAX mayor disminuyó en un 0,3% y FRAX cadera en un 0,1%, Los eventos adversos se presentaron con mayor proporción en el grupo de ácido zoledrónico. La incidencia de fracturas en ambos grupos fue baja. CONCLUSIONES Los medicamentos evaluados en el presente estudio mostraron ser efectivos dentro de su grupo de tratamiento y no se evidenciaron diferencias en las efectividades entre grupos, por tanto, la decisión de la elección del tratamiento es del médico tratante y debe ser individual a cada paciente. | spa |
| dc.description.abstract | INTRODUCTION Postmenopausal osteoporosis affects a large proportion of women in the world, most of them over the age of 50, incidence of the disease will continue to increase given the aging population that is accompanied by an increase in the total risk of fractures. OBJECTIVE Evaluate the effectiveness of zoledronic acid compared to ibandronic acid for the management of postmenopausal osteoporosis in populations of Medellin and Bogota belonging to IPS Helpharma, who received treatment for a period of 2 to 4 years. METHODS Analytical, cohort, retrospective study of 277 patients diagnosed with postmenopausal osteoporosis. The patients were treated for a period of 2 to 4 years at IPS Helpharma in towns of Bogota and Medellin. We included 56 patients treated with ibandronic acid and 221 treated with zoledronic acid. We conducted a stratified random sample by proportional allocation and the distribution by towns was Bogota (n: 99 patients) and Medellin (n: 178 patients). RESULTS Ibandronic acid obtained a greater gain in T-score lumbar than femoral level (6% vs 1,5%), major FRAX decreased by 0,5% and the hip FRAX had a gain of 0,1%. zoledronic acid showed a gain in lumbar T-score of 11% and femoral of 5,4%, major FRAX decreased by 0,3% and hip FRAX by 0,1%. Adverse events were presented with a higher proportion in zoledronic acid group. The incidence of fractures in both groups was low. CONCLUSIONS: The medications evaluated in the present study showed to be effective within their treatment group and there were no differences in effectiveness between groups, therefore, decision of the choice of treatment is of the doctor and must be individual to each patient. | eng |
| dc.description.embargo | 2019-09-29 01:01:02: Script de automatizacion de embargos. info:eu-repo/date/embargoEnd/2019-09-28 | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.doi | https://doi.org/10.48713/10336_13789 | |
| dc.identifier.uri | http://repository.urosario.edu.co/handle/10336/13789 | |
| dc.language.iso | spa | |
| dc.publisher | Universidad del Rosario | spa |
| dc.publisher.department | Facultad de medicina | spa |
| dc.rights.accesRights | info:eu-repo/semantics/openAccess | |
| dc.rights.acceso | Abierto (Texto Completo) | spa |
| dc.rights.cc | Atribución-NoComercial-SinDerivadas 2.5 Colombia | spa |
| dc.rights.licencia | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | |
| dc.source.bibliographicCitation | 1. Zanchetta, José, I.O.F. CdELdl. Osteoporosis: epidemiología, costo e impacto en América Latina Noviembre 2012 [Nº 41: 50-56:[Available from: http://tendenciasenmedicina.com/Imagenes/imagenes41/art_08.pdf. | |
| dc.source.bibliographicCitation | 2. Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporosis International. 2009;20(2):275-82. | |
| dc.source.bibliographicCitation | 3. DANE. Demografìa y población 2017 [Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion. | |
| dc.source.bibliographicCitation | 4. Ardila E. Epidemiology of osteoporosis in Colombia. Bone. 2001;29:297. | |
| dc.source.bibliographicCitation | 5. Carmona F. Osteoporosis en Santa Fe de Bogotá. 1999. | |
| dc.source.bibliographicCitation | 6. M M-T, Varsavsky M, MD AP. Osteoporosis. Definición. Epidemiología. Rev Osteoporos Metab Miner. 2010;2 (Supl 3): S5-S7. | |
| dc.source.bibliographicCitation | 7. International, Foundation O. FRAX Identificando personas con riesgo elevado de fractura2009. Available from: https://www.iofbonehealth.org/sites/default/files/PDFs/WOD%20Reports/FRAX_report_09_es.pdf. | |
| dc.source.bibliographicCitation | 8. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal of Clinical Investigation. 2005;115(12):3318-25. | |
| dc.source.bibliographicCitation | 9. Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core evidence. 2009;4:13-23. | |
| dc.source.bibliographicCitation | 10. Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. New horizons in treatment of osteoporosis. DARU Journal of Pharmaceutical Sciences. 2017;25(1):2. | |
| dc.source.bibliographicCitation | 11. M.J. GdTR, Sosa Henríquez M. Osteoporosis: definición, tendencia epidemiológica, avances en la fisiopatología y clínica 2014 [Available from: https://www.clinicalkey.es/#!/content/playContent/1-s2.0-S030454121470811X?returnurl=http:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS030454121470811X%3Fshowall%3Dtrue&referrer=http:%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS030454121470811X | |
| dc.source.bibliographicCitation | 12. Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clinical Interventions in Aging. 2015;10:583-91. | |
| dc.source.bibliographicCitation | 13. Centre for Metabolic Bone Diseases UoS, UK. FRAX ® Fracture Risk Assessment Tool 2008 [Available from: https://www.sheffield.ac.uk/FRAX/tool.aspx?country=28. | |
| dc.source.bibliographicCitation | 14. McCloskey EV, Harvey NC, Johansson H, Kanis JA. FRAX updates 2016. Current Opinion in Rheumatology. 2016;28(4):433-41. | |
| dc.source.bibliographicCitation | 15. Murphy-Menezes M. Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis. Clinical Therapeutics. 2015;37(7):1573-86. | |
| dc.source.bibliographicCitation | 16. Leslie WD, University of Manitoba W, Canada, Department of Medicine (C5121) UoM, 409 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6., Lix LM, University of Saskatchewan S, Canada, Johansson H, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? Journal of Bone and Mineral Research. 2012;27(6):1243-51. | |
| dc.source.bibliographicCitation | 17. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. European Journal of Rheumatology. 2017;4(1):46-56. | |
| dc.source.bibliographicCitation | 18. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International. 2014;25(10):2359-81. | |
| dc.source.bibliographicCitation | 19. Mottaghi P. Intravenous bisphosphonates for postmenopausal osteoporosis. Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences. 2010;15(3):175-84. | |
| dc.source.bibliographicCitation | 20. Carmona R, Adachi R. Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid. Patient preference and adherence. 2009;3:189-93. | |
| dc.source.bibliographicCitation | 21. Soares AP, do Espírito Santo RF, Line SRP, Pinto MdGF, Santos PdM, Toralles MBP, et al. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development. Environmental Toxicology and Pharmacology. 2016;42:212-7. | |
| dc.source.bibliographicCitation | 22. Chao M, Hua Q, Yingfeng Z, Guang W, Shufeng S, Yuzhen D, et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pakistan Journal of Medical Sciences. 2013;29(6):1381-4. | |
| dc.source.bibliographicCitation | 23. Cole R. Postmenopausal osteoporosis: another approach to management. - Abstract - Europe PMC. Journal of Family Practice. 2010;59(6). E1-E7. | |
| dc.source.bibliographicCitation | 24. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, et al. Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. Journal of the American Geriatrics Society. 2010;58(2):292-9. | |
| dc.source.bibliographicCitation | 25. Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, et al. Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial. Bone. 2012;50(6):1389-93. | |
| dc.source.bibliographicCitation | 26. Hamdy RC. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Design, Development and Therapy. 2010;4:321-35. | |
| dc.source.bibliographicCitation | 27. Sunyecz JA. Zoledronic acid infusion for prevention and treatment of osteoporosis. International Journal of Women's Health. 2010;2:353-60. | |
| dc.source.bibliographicCitation | 28. Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug, healthcare and patient safety. 2010;2:121-37. | |
| dc.source.bibliographicCitation | 29. Rizzoli R, Reginster J-Y, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, et al. Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International. 2011;89(2):91-104. | |
| dc.source.bibliographicCitation | 30. Miller PD. The kidney and bisphosphonates. Bone. 2011;49(1):77-81. | |
| dc.source.bibliographicCitation | 31. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International. 2008;74(5):641-8. | |
| dc.source.bibliographicCitation | 32. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine. 2007;356(18):1809-22. | |
| dc.source.bibliographicCitation | 33. Tian Y, Wang R, Liu L, Ma C, Lu Q, Yin F. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. BMC Musculoskeletal Disorders. 2016;17:72. | |
| dc.source.bibliographicCitation | 34. Peterson JD, Bedrossian EH. Bisphosphonate-Associated Orbital Inflammation—A Case Report And Review. Orbit. 2012;31(2):119-23. | |
| dc.source.bibliographicCitation | 35. Räkel A, Boucher A, Ste-Marie L-G. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clinical Interventions in Aging. 2011;6:89-99. | |
| dc.source.bibliographicCitation | 36. Adler RA, Fuleihan GE-H, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2016;31(1):16-35. | |
| dc.source.bibliographicCitation | 37. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. 2017;12(1):43. | |
| dc.source.bibliographicCitation | 38. Frampton JE, Perry CM. Ibandronate. Drugs. 2008;68(18):2683-707. | |
| dc.source.bibliographicCitation | 39. Black DM, Rosen CJ. Postmenopausal Osteoporosis. New England Journal of Medicine. 2016;374(3):254-62. | |
| dc.source.bibliographicCitation | 40. Amling M, Kurth A. Ibandronate: A Review of its Vertebral and Nonvertebral Antifracture Efficacy. Women's Health. 2009;5(5):467-73. | |
| dc.source.bibliographicCitation | 41. Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y. Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis. Medicine. 2015;94(26):e1007. | |
| dc.source.bibliographicCitation | 42. Hagino H, Yoshida S, Hashimoto J, Matsunaga M, Tobinai M, Nakamura T. Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study. Calcified Tissue International. 2014;95(6):557-63. | |
| dc.source.bibliographicCitation | 43. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International. 2012;23(6):1769-78. | |
| dc.source.bibliographicCitation | 44. Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. International Journal of Women's Health. 2015;7:7-17. | |
| dc.source.bibliographicCitation | 45. Fit KE, Burkiewicz JS, Griffin BL, Meyer CM. Acute Phase Reaction with Intravenous Ibandronate. The American Joournal of Medicine; 2008. | |
| dc.source.bibliographicCitation | 46. Weber I, Olaiwan A, Bonte I, Artigou C, Pras-Landre Vr, Moguelet P, et al. Adverse cutaneous drug reactions to ibandronate. European Journal of Dermatology. 2017;21(4):591-4. | |
| dc.source.bibliographicCitation | 47. D. Miller P, Ragi-Eis S, Mautalen C, Ramirez F, Jonkanski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease — The DIVINE study. Bone. 2011;49(6):1317-22. | |
| dc.source.bibliographicCitation | 48. Jackson RD, Lacroix, Andrea Z. Calcium plus Vitamin D Supplementation and the Risk of Fractures - ProQuest. 2006. | |
| dc.source.bibliographicCitation | 49. Monge-Vargas L, Sáenz-Campos DyU-C, Roxana. Efectividad del alendronato más calcio y vitamina D, comparado con calcio y vitamina D para la prevención de la fractura de cadera. Acta méd costarric. 2017;59(2):79-. | |
| dc.source.bibliographicCitation | 50. Miller PD, Recker RR, Harris, S, Silverman, S, Felsenberg, D, Reginster, J, Day, B-M, Barr, C, Masanauskaite, D. Long-term fracture rates seen with continued ibandronate treatment: Pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporosis International. 2014;25::349–57. | |
| dc.source.bibliographicCitation | 51. Salud Md. Resolución Número 8430. 04 de Octubre de 1993. | |
| dc.source.bibliographicCitation | 52. Mundial AM. WMA - The World Medical Association-Declaración de Helsinki de la AMM – Principios éticos para las investigaciones médicas en seres humanos. 2013. | |
| dc.source.instname | instname:Universidad del Rosario | spa |
| dc.source.reponame | reponame:Repositorio Institucional EdocUR | spa |
| dc.subject | Bifosfonatos | spa |
| dc.subject | Riesgo de fractura a diez años (FRAX) | spa |
| dc.subject | Densidad ósea (DMO) | spa |
| dc.subject.ddc | Enfermedades | |
| dc.subject.decs | Cumplimiento de la medicación | spa |
| dc.subject.decs | Fracturas óseas | spa |
| dc.subject.decs | Osteoporosis posmenopáusica | spa |
| dc.subject.keyword | (FRAX) Fracture Risk Assessment Tool. | eng |
| dc.subject.keyword | Fractures bone | eng |
| dc.subject.keyword | Medication adherence | eng |
| dc.subject.keyword | Osteoporosis postmenopausal. | eng |
| dc.subject.keyword | Bone Density | eng |
| dc.subject.keyword | Diphosphonates | eng |
| dc.title | Efectividad del Ácido Ibandrónico y Ácido Zoledrónico en el tratamiento de osteoporosis postmenopáusica : estudio multicéntrico. | spa |
| dc.type | bachelorThesis | eng |
| dc.type.hasVersion | info:eu-repo/semantics/acceptedVersion | |
| dc.type.spa | Trabajo de grado | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- OSTEOPOROSIS POSTMENOPAUSICA_VERSION FINAL 28-SEP-2017.pdf
- Tamaño:
- 1.06 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
